Mamoun Younes

Mamoun Younes

Auto-generated profile, based on publicly available information

Mamoun Younes

Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston McGovern Medical School, and Memorial-Hermann Hospital-TMC, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 1997 in Cancer
Verified
Journal Article
Open access
PDF file
MYMamoun Younes
Mamoun Younes
RBRichard W. Brown
Richard W. Brown
MSMark Stephenson
Mark Stephenson
MGMargaret Gondo
Margaret Gondo
PCPhilip T. Cagle
Philip T. Cagle
BACKGROUND Increased expression of Glut1 and Glut3 has been reported in many human cancers, including nonsmall cell lung carcinoma (NSCLC). The aim of this study was to determine the biologic significance of Glut1 and Glut3 overexpression in Stage I NSCLC. METHODS Using immunohistochemistry and polyclonal anti‐Glut1 and anti‐Glut3 antibodies, the authors immunostained sections of formalin fixed, paraffin embedded tissues from 289 Stage I NSCLCs. The Kaplan‐Meier survival method, the log rank test, and Fisher's exact test were used for statistical analysis. RESULTS Of the 289 cases, 49 (17%) were negative for both Glut1 and Glut3, 239 (83%) were Glut1 positive, 61 (21%) were Glut3 positive, 179 (62%) were positive for Glut1 but negative for Glut3, 1 (0.3%) was positive for Glut3 but negative for Glut1, and 60 (21%) were positive for both Glut1 and Glut3. Only 1 of 50 Glut1 negative tumors (2%) was positive for Glut3, whereas 60 of 239 Glut1 positive tumors (25%) were positive for Glut3 (P < 0.0001). Glut1 or Glut3 were detected more often in poorly differentiated and undifferentiated tumors (P <0.0001 and P = 0.0008, respectively). Overexpression of Glut1 and/or Glut3 was associated with poorer survival (P = 0.0133), especially in patients with well‐differentiated and moderately differentiated tumors (P = 0.0017). CONCLUSIONS In Stage I NSCLC, Glut3 overexpression likely occurs after Glut1 overexpression. The appearance of Glut1 positive clones is associated with aggressive biologic behavior, which is worsened by the emergence of Glut3 positive clones. Glut1 and Glut3 are significant of poor prognosis indicators in cases of NSCLC. Cancer 1997; 80:1046‐51. © 1997 American Cancer Society.

1 August 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NHNaoko Honma
Naoko Honma
RHRie Horii
Rie Horii
TITakuji Iwase
Takuji Iwase
SSShigehira Saji
Shigehira Saji
MYMamoun Younes
Mamoun Younes
GSGoi Sakamoto
Goi Sakamoto
Purpose: The clinicopathologic importance of a second estrogen receptor (ER), ER-β, in breast cancers has been intensely studied; however, there is still no real consensus regarding the clinical utility of an ER-β assay, probably because of the lack of standardized methodology, the presence of several ER-β isotypes (ER-β1-5, and so on), and, more importantly, the lack of convincing data on whether the ER-β status provides clinically useful information over what is already provided by the traditional ER-α/progesterone receptor (PR) assay. A large and systematic study is needed to address these important issues. Patients and Methods: Archival materials of 442 invasive breast cancers from women treated with adjuvant tamoxifen monotherapy and with a long follow-up period (median, 11.1 years) were subjected to immunohistochemical study using three commercially available anti–ER-β antibodies that detect ER-β1-3 (ER-βN), ER-β1, and ER-βcx (ER-β2). Results: Positive staining for ER-βN or ER-β1 was associated with significantly better survival. By contrast, ER-βcx status did not influence survival. In multivariate analysis, ER-β1 status emerged as an independent predictor of recurrence and mortality. ER-β1 status was significantly associated with survival in postmenopausal, but not premenopausal, women. Importantly, ER-β1 positivity was associated with significantly better survival in patients with ER-α–negative/PR-negative or ER-α–negative/PR–negative/human epidermal growth factor receptor 2–negative (triple-negative) tumors, which are widely believed to be hormone unresponsive, have poor prognosis, and require chemotherapy. Conclusion: Immunohistochemical examination of ER-β1 in addition to ER-α and PR is clinically important in patients with breast cancer treated with tamoxifen monotherapy. Further studies are needed to confirm our findings.

12 May 2006 in Cancer
Verified
Journal Article
Open access
PDF file
SSSteven S. Shen
Steven S. Shen
CSCarolyn L. Smith
Carolyn L. Smith
JHJer‐Tsong Hsieh
Jer‐Tsong Hsieh
JYJiang Yu
Jiang Yu
IKIsaac Y. Kim
Isaac Y. Kim
SLSeth P. Lerner
Seth P. Lerner
BACKGROUND Estrogen receptors (ERs) are known to mediate important physiologic responses as well as the growth of some tumors in response to estradiol stimulation. In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERβ‐positive bladder cancer cell line. However, the expression of ERβ in human bladder cancer has not been thoroughly investigated. METHODS ERα and ERβ expression in 224 bladder tumor samples was evaluated using tissue microarray and immunohistochemistry. Levels of ERα and ERβ protein and mRNA expression were determined in several bladder cancer cell lines using quantitative reverse‐transcriptase polymerase chain reaction (RT‐PCR) and Western blot analysis. The effect of estradiol and antiestrogen treatments on RT4 bladder cancer cell growth was determined by cell proliferation assays. RESULTS Analyses revealed that only 2 human bladder cancers weakly expressed ERα. In contrast, the expression of ERβ was detected in 141 tumors (63%). ERβ was expressed in 58% of WHO Grade 1 and 2 tumors, whereas 70% of Grade 3 tumors demonstrated expression (P=.085). Importantly, although only 53% and 55% of Ta and T1 tumors demonstrated ERβ expression, 80% of T2, 81% of T3, and 75% of T4 tumors showed ERβ expression. The differences in ERβ expression between Ta/T1 and T2/T3/T4 tumors were found to be highly significant (P<.001). Metastatic transitional cell carcinomas had ERβ expression (80%) comparable to that of muscle invasive bladder cancers. Western blot analysis detected ERβ protein expression in each of the 5 bladder cancer cell lines tested, whereas no or very low levels of ERα were found. Quantitative RT‐PCR revealed that higher levels of ERβ than ERα mRNA were present in 5637, T‐24, TSU‐Pr1, and TCC‐Sup bladder cancer cells, whereas ER‐α mRNA levels were greater than ERβ in RT4 cells. Treatment with 17β‐estradiol modestly increased RT4 cell growth, whereas the antiestrogens, 4‐hydroxtamoxifen, raloxifene, or ICI 182,780 inhibited the growth of RT4 cells. CONCLUSIONS ERβ is the dominant receptor expressed in bladder cancer cell lines and in the majority of human bladder tumors. Moreover, the degree of ERβ expression increases with increasing stage and grade of differentiation. Antiestrogens have an inhibitory effect on the growth of bladder cancer cells in vitro. Cancer 2006. © 2006 American Cancer Society.

1 August 2003 in Blood
Verified
Journal Article
Open access
PDF file
BZBei Zheng
Bei Zheng
PFPaolo Fiumara
Paolo Fiumara
YLYang V. Li
Yang V. Li
GGGeorgios Georgakis
Georgios Georgakis
VSVirginia Snell
Virginia Snell
AYAnas Younes
Anas Younes
The mitogen-activated protein kinase (MAPK) (also called extracellular signal–regulated kinase [ERK]) pathway has been implicated in malignant transformation and in the regulation of cellular growth and proliferation of several tumor types, but its expression and function in Hodgkin disease (HD) are unknown. We report here that the active phosphorylated form of MAPK/ERK is aberrantly expressed in cultured and primary HD cells. Inhibition of the upstream MAPK kinase (also called MEK) by the small molecule UO126 inhibited the phosphorylation of ERK and demonstrated a dose- and time-dependent antiproliferative activity in HD cell lines. UO126 modulated the levels of several intracellular proteins including B-cell lymphoma protein 2 (Bcl-2), myeloid cell leukemia–1 (Mcl-1) and caspase 8 homolog FLICE-inhibitory protein (cFLIP), and induced G2M cell-cycle arrest or apoptosis. Furthermore, UO126 potentiated the activity of apoliprotein 2/tumor necrosis factor–related apoptosis-inducing ligand (APO2L/TRAIL) and chemotherapy-induced cell death. Activation of CD30, CD40, and receptor activator of nuclear kappaβ (RANK) receptors in HD cells by their respective ligands increased ERK phosphorylation above the basal level and promoted HD cell survival. UO126 inhibited basal and ligand-induced ERK phosphorylation, and inhibited ligand-induced cell survival of HD cell lines. These findings provide a proof-of-principle that inhibition of the MEK/ERK pathway may have therapeutic value in HD.

1 August 1990 in Cancer
Verified
Journal Article
Closed access
PDF file
MYMamoun Younes
Mamoun Younes
JSJeffrey Sussman
Jeffrey Sussman
LTLawrence D. True
Lawrence D. True

1 January 2001 in Human Pathology
Verified
Journal Article
Closed access
SMSherri Mann
Sherri Mann
RLRodolfo Laucirica
Rodolfo Laucirica
NCNicole Carlson
Nicole Carlson
PYPamela S. Younes
Pamela S. Younes
NANajeeba Ali
Najeeba Ali
MYMamoun Younes
Mamoun Younes